Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik

At the Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik in Munich, research in nervous system diseases and musculoskeletal diseases focuses strongly on inherited neuromuscular disorders such as myotonic dystrophy and myotonic dystrophy type 1. These studies are designed to test new therapies, assess safety and tolerability, and explore whether treatments can improve symptoms like muscle stiffness and hand myotonia.

• Investigating myotonic dystrophy type 1 with a focus on treatment safety and symptom improvement
• Evaluating whether new therapies can reduce hand myotonia and support daily function
• Studying long-term treatment effects in chronic neuromuscular disease

Several trials here aim to better understand how emerging medicines may help people living with these progressive genetic conditions.

Research in nutritional and metabolic diseases and congenital and hereditary disorders includes studies of Fabry disease, Pompe disease, and primary mitochondrial disease. The main goal is to evaluate new treatments that may ease pain, improve muscle or heart-related symptoms, and support better disease control in rare inherited conditions.

• Assessing therapies for Fabry disease to help with neuropathic and abdominal pain
• Testing treatment options for late-onset Pompe disease with attention to safety and tolerability
• Exploring approaches for primary mitochondrial disease linked to myopathy and cardiomyopathy

These trials reflect a broad effort to improve care for rare metabolic diseases through better symptom management and therapeutic development.

The site also contributes to research on rare genetic diseases by studying treatments aimed at underlying disease mechanisms rather than only symptoms. Across these projects, investigators are evaluating whether new medicines can be safely used and whether they may lead to meaningful clinical benefit in conditions with limited treatment options.

• Testing new therapies for inherited disorders with few established treatment choices
• Measuring safety, tolerability, and early signs of effectiveness
• Supporting development of targeted care for patients with complex multisystem disease

The research portfolio at this clinical trial site is centered on improving outcomes for patients with challenging and often long-term neurological and metabolic disorders.